Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes it would be great for Boxing....and other such sports
Arch Therapeutics Science
http://sciencebehindac5.blogspot.com/
This is the key agreement and it will be in October 2016 imho.
partnership distribution agreement for Europe
CE Mark should take less than 2 months at most.
Arch (ARTH) CEO Dr. Norchi UP CLOSE AND PERSONAL
Arch CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund.
Terrence W. Norchi, MD; President, CEO, Director, Co-Founder
Terrence W. Norchi, MD is President and Chief Executive Officer of Arch Therapeutics, a company he co-founded in 2006 and led from an early stage of research to its current stage of development.
Prior to Arch Therapeutics, Dr. Norchi was a portfolio manager, and pharmaceutical analyst, and head of the healthcare team at Putnam Investments. Previously, he was the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management. Prior to that he was s sell-side pharmaceutical analyst at Sanford C. Bernstein in New York City.
He earned an M.B.A. from the MIT Sloan School of Management in 1996. Dr. Norchi completed internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as Chief Medical Resident. He earned an M.D. degree in 1990 from Northeast Ohio Medical University.
Here are conference notes from call with Dr. Terrence Norchi
Regarding CEO “I teach diversification but for me ARCH is my PORTFOLIO”
“Never seen anything like AC5…..”
Goal in Life : “Get product out in market and make a difference in lives” “Profit for all especially investors who have supported the Company”
“I rely on my perserverance….beat people by my perserverance…”
“does not rely on being smarter…”
“Run faster, harder and longer than the next guy…formula for my success”
‘Work ass off until you get it done”
“Listen before respond….” END
Regarding AC5
AC5-“not sticky or gunky”
Anytime an incision or hole is made in the body one must worry about…..
Must worry about bleeding, leaking and contamination…. Try to mitigate infection
Goal is normal healing….bleeding stresses organs so AC5 would reduce/eliminate and thus enhance healing
Stops bleeding in seconds as opposed to competitors minutes
AC5 goes away in 10 to 14 days…AC5 amino acids breaks down.. Most excreted other absorbed
Very High Margins for AC5--$ 400 -$500 typical Revenue application --2cm by 2 cm area typical app ½ ml to 1 ml Normal AC5 package sizes 3ml to 5 ml “ A lot of money for little product”
“When you save time by Surgeon and time in Operation Room (OR) you save substantial dollars. Saving 10 to 15 minutes in OR means hundreds of dollars savings. “
Cost to get to market as medical device “not a lot of money”
CEO has come up with a list of 200 applications of AC5 of which one of the more interesting:
Bigger than surgical bleeding.. Bowel surgery
3-15% chance of leakage…feces, etc etc
Of this 15% will die
Of this 50% need another surgery at a cost of $100,000
AC5 could be gestational intestinal sealants …gut ..to prevent above
Here is copy from internet of above:
“Anastomotic leakage rates following colon resection range on average from 3-15%.1 Such leakage is considered the most serious complication of bowel repair, causing one third of mortalities occurring after colorectal surgery. There is a high clinical and economic need for a product that effectively reduces anastomotic leakage rates, due to the following:
• Leaking anastomoses double the length of stay and increase mortality rates as much as ten-fold
• Reoperation rates after leakage can be as high as 87%
• Beyond the initial mortality risk, overall five year survival rates for patients with anastomotic leakage are reduced by 20%
• Anterior rectal resections have the highest leakage rate, up to 24%
• Crohn’s disease patients carry a significant risk of anastomotic dehiscence (12%) even when macroscopically normal margins are obtained”
Also target hard to heal skin such as foot ulcers…..
Also for burn victims…
AC5 very different than competition
Biogradable
Biocompatible
Non-clotting (most are clotting)
Creating barrier instead of a Clot
Clear / See Through so no barrier to surgery
Liquid or powder
Builds a barrier
Product Safe
Operate Through
Slash Operating room times (also need for preoperative blood transfusions)
Dr. KSS--- please join the best on the internet --$49—Website—
www.stockgumshoe.com/author/dr-kss-md-phd/
Small sampling of the best biotech site on the planet:
“For Norchi as a physician it is the most amazing reagent or substance he has ever seen (I agree…I feel the same way). He wants his life’s work to be getting this to market.”
“Norchi is NOT going to prove to be some dark actor or bad guy in this. Quite the opposite. You need to understand his psychology. Physicians tend to be rather hung up on where each other went to medical school, and sometimes, such as when residencies start, graduates of state medical schools can almost feel unworthy to be in the same room as Ivy League med school grads.
Norchi is a product of a small unknown medical school in eastern Ohio, not a good one. Doesn’t mean he’s no good, but rather that he may have been a late bloomer in college. If he went to this school, it’s because he had no other options. Since that time, I feel Norchi has been desperate to prove himself in the form of successively higher accomplishments.
He got into the best medical residency he could under the circumstances, and busted his backside, and made it to chief resident—-hard to do. Then he grabbed an Ivy MBA. Then he buddied up with Dr. Ellis-Behnke, who is a hot and respected academic property in materials science, and got his name on a patent. He ran a healthcare mutual fund.
At every stage, Norchi is trying to add to his stature and respectability, and he has the personality type that if he did something to fleece or scam people, I don’t think he could face himself in the mirror. He wants to be a star and to be regarded as honest. And as I see it, he is. I like him….he is decent and real, and fun to brainstorm with. He has a good head. He loves to laugh at good jokes.”
Elevator Summary of ARCH
www.archtherapeutics.blogspot.com/
ARCH THERAPEUTICS (ARTH) DUE DILIGENCE ASSISTANCE
Dear Mom
How could a clear liquid be deemed a medical device??
A CLEAR LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE. See You Tube Video Below–LIVER. Stops Bleeding in seconds……
See reason why this clear liquid is deemed a medical device in Europe human trials below also.
The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund.
The clear liquid medical device called AC5 is used to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. This is a most unusual medical device with vast impact on Surgery, Trauma Care, Wound Care (Pressure Ulcers, Foot Ulcers, Burns, etc), Military and other emergency situations. OVER 200 Potential APPLICATIONS. Human trials have begun in Ireland for this medical device Note MIT’s involvement.
The Company is Arch Therapeutics (Symbol ARTH)
Website WWW.ARCHTHERAPEUTICS.COM/
The Cheapest Medical Device Stock I’ve Ever Seen By Michael Murphy CFA
HTTP://SEEKINGALPHA.COM/ARTICLE/3286585-THE-CHEAPEST-MEDICAL-DEVICE-STOCK-IVE-EVER-SEEN
Arch Therapeutics has Initiated Human Clinical Trials in Europe–The Company has identified over 200 potential areas where AC5 could be used including: Surgery, Trauma Care, Wound Care, Military, Adhesions, Pressure Ulcers (Bedsores) (2.5 million cases in USA with annual cost $ 10 billion), Foot Ulcers, Burns, etc.
Presentation by Founder of AC5 Dr. Rutledge Ellis-Behnke PHD using AC5 on animals
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
You Tube Video
HTTPS://WWW.YOUTUBE.COM/WATCH?V=WWYHGYUSONQ&APP=DESKTOP
Dr. Rutledge Ellis-Behnke, PhD Linkedin BIO HTTPS://WWW.LINKEDIN.COM/IN/NANOMEDICINE
COMPANY Presentation (page 20 Foot ulcers-Pressure Ulcers, Burns)
HTTP://CONTENT.STOCKPR.COM/ARCHTHERAPEUTICS/MEDIA/A615BA3D0A9C00B0E77D846E84303000.PDF
Company Video HTTPS://WWW.YOUTUBE.COM/WATCH?V=-KUVC–OKFI
Arch Therapeutics, Inc. (Symbol ARTH)
Faster, Safer, Simpler Surgery
Arch is a small public company with a medical device pathway, relatively low capital requirements and potentially high margin novel products targeting large growing markets. Expect first product approval in 2016.
Arch Medical Device: A LIQUID noncoagulant homostatic agent known as “AC5.” Works in presence of “blood thinners.” Only one that does.
Scientists at Massachusetts Institute of Technology invented this universal fix-all hemostat that works in a few seconds.
AC5 is used to stop bleeding (hemostasis) and control leaking (sealant). Spray AC5 on a bleeding artery and the bleeding stops without mechanical pressure being needed in seconds.
Elevator Summary of Company HTTP://WWW.ARCHTHERAPEUTICS.BLOGSPOT.COM/
The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery (some have estimated potentially up to 60%).
Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection. Arch’s AC5 to address these needs. Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.
Human Clinical Trials have begun in Ireland. Total Europe and USA human trial cost estimated to be $8 to $12 million. Tiny in Biotech world.
The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund
Arch Therapuetic AC5 Surgical Hemostatic Device
Attributes of AC5
Synthetic peptide
Clear liquid, squirted or sprayed– Can see and operate through it
Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body)
Classified as Medical Device in Europe because of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes
Stops bleeding promptly
Faster time to stop bleeding versus five different popular marketed products
Blood thinner agnostic—only hemostasis product that is.
Efficacy even in presence of “blood thinners”
Bioasborbable
Natural amino acids, non-animal
Enables normal healing
Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer
Stores at room temperature
Indefinite shelf life
Simple, effective, versatile, safe universal
There are many other hemostatic agents, but:
* They all rely on using the patient’s blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch’s AC5 product solves all these problems.
Please do you own due diligence.
Love,
REG
Murphy failed to focus on the 200 +- applications of AC5. The low hanging fruit being the external applications such as Pressure Ulcers, Foot Ulcers, Burns etc.
I hope we are going to get to see what the 200 applications are.
This is an application that has not been discussed here:
“Not to mention use of AC5 as sealant in Bowel surgery ($ 6 Billion Market) whereby there is a 2-15% chance of anastomotic leakage of fecal matter, etc.”
AC5 is used to stop bleeding (hemostasis) and control leaking (sealant). Spray AC5 on a bleeding artery and the bleeding stops without mechanical pressure being needed in seconds.
Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection. Arch’s AC5 to address these needs. Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.
Elevator Summary of Arch http://www.archtherapeutics.blogspot.com/
The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery (some have estimated potentially up to 60%).
Soooo True. Arch needs institutional ownership to get to the next level. Dr. Norchi who I like you have met is tailored to go after the institutions.
The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund.
CEO Dr. Norchi: "I teach diversification but have ALL my eggs are in Arch."
Elevator Summary of ARCH http://www.archtherapeutics.blogspot.com/
The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery (some have estimated potentially up to 60%).
Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection. Arch’s AC5 to address these needs. Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.
Framingham biotech co. close to data in first clinical study
BY LAURA FINALDI
7/20/2016
Arch Therapeutics is in the midst of its first clinical trial, an assessment of the safety and performance of its bleeding control device in humans, the company said.
The Framingham-based company has enrolled 46 patients in its randomized controlled single-blind study to test its AC5 Surgical Hemostatic Device, which can be used to control bleeding and loss of other fluids, in order to provide quicker and safer surgical and interventional care.
The study is taking place in Ireland, and results should be available at some point this summer, after 30-day follow up assessments and subsequent statistical analysis are completed.
Dr. Terrence W. Norchi, president and CEO of Arch Therapeutics, said this is another step on towards regulatory approval of AC5.
“We are eager to obtain the data when the statistical analysis is available, and we look forward to reporting the results later this summer,” Norchi said in a statement.
Arch is collaborating on the study with CURAM, Science Foundation Ireland Centre for Research in Medical Devices and the Clinical Research Facility based at National University of Ireland Galway.
Arch Therapeutics has five employees -- one part time and four full time -- and a spokesperson said the company makes extensive use of third-party contractors, consultants and advisers.
http://www.wbjournal.com/ARTICLE/20160720/NEWS01/160729991
Who knows.... any time from now to end of Summer. To be conservative pick end of summer August 31 to September 6
You are quite welcome. We all should be relieved to understand what the Arch Flash Crash was all about. I did this analysis to figure it out myself.
Arch should have $1.9 million more cash and everything else should be same. IMHO the price should be back to pre-Arch Flash Crash levels. It is like a tornado came through and left.
The Arch Flash Crash Analysis
What happened on July 14, 2016 to ARTH
So I decided to dig deeper after the July 14, 2016 Arch decline when 8,730,581 shares traded and the Arch market price fell $.205 or 25.79% to $.59 a share.
July 14 , 2016 happens to be the SEC effective date for Arch S-1 registration of the May 26, 2016 private placement of 9,418,334 shares of Arch at $.36 and a Series E Warrant to purchase .75 shares or 7,063,750 shares at $ .438 per share EXPIRING May 26, 2021 (5/26/21 !) to 18 investors (12 of which had participated in the 6/30/15 Arch financing for $ 3.166 million for stock at $ .22 and one Series D warrant at $ .25 share expiring 6/30/20)
What was different about the May 26, 2016 Arch private placement:
1) This was the first private placement where less than one warrant was issued with the purchase of one share. In this case it was one share and only .75 warrant.
2) I knew that the 6/30/15 Arch private placement to 19 investors did not result in a decline in the Arch market price upon registration of the shares and warrants. These were high quality long term investors who believed in Arch. I had studied each one them. Some of them were there to provide funding by exercising their warrants. I understood this as they had a purpose.
3) Maxim Group LLC (“Maxim”) was the exclusive institutional investor placement agent for the May 2016 Arch Private placement. They did not participate in prior Arch private placements. I knew Maxim has the very worst reputation on Wall Street for toxic financings and king of death spiral financing.
Maxim was bringing what I call “hot money” into the Arch private placement. All the prior Arch financings were with long term investors.
So the ‘hot money” Maxim investors were six in number whose only interest was to flip the Arch shares and warrants at a profit. As far as these investors were concerned Arch could have been operating in any industry. They did not care.
4) So the Maxim "hot money" in the May 26, 2016 private placement was $ 2,084,000 out of total $ 3,390,600 or 61 %.
The Maxim "hot money" represented 5,788,889 common shares and 4,341,667 warrants or 10,130,556 total. The 4,341,667 Series E warrants that expire 5/26/21 at .438 per warrant or $ 1,901,650 were probably exercised by the Maxim “hot money ” resulting in more cash to Arch.
On July 14, 2016 the date of the S-1 being effective 8,730,581 shares traded and the Arch market price fell $.205 or 25.79% to $.59.
Conclusions: At first I was upset about this then I thought as a shareholder this is actually good because 61% of the Series E warrants expiring 5/26/21 were exercised for cash (to be confirmed by the 6/30/16 Form 10-Q which will be filed in a few weeks) totaling $ 1.9 million.
Prior to the exercise by Maxim “hot money” $ 1.9 million of Series E warrants Arch needed $6.1 million to $ 10.1 million of additional capital for Full Europe and US human trials for the 200 +/- AC5 applications. For biotech these are very small dollars.
By Maxim investors early exercising the warrants it means less cash capital will have to be raised by Arch in the future. Thus less dilution. This is great. As shareholders we want all warrants to be exercised EARLY.
In fact Arch private placement investors have a history of early exercise of their warrants (as shareholders we want this):
Warrant Series A Expires 2/14/19 outstanding 4.0 M At $.20 76.6% have already exercised Original issued 17.1 M
Warrant Series C Expires 7/02/16 outstanding 1.1 M At $.20 90.3% have already exercised Original issued 11.4 M
Warrant Series D Expires 6/30/20 outstanding 11.2 M At $.25 22.2% have already exercised Original issued 14.4 M
Warrant Series E Expires 5/26/21 outstanding 7.1 M At $.438 Possibly Maxim “hot money” just exercised 4.3 million or 61% of the total.
If the Maxim “hot money” has exited imho Arch should return to where it was before but now financially much stronger. The offering to Maxim was in many ways the equivalent to a shelf offering. In retrospect the 8.7 million shares traded on July 14, 2016 were absorbed well by the market. This was the Arch "Flash Crash." This is my analysis of the “Arch Flash Crash” and it may differ from actual events but I sincerely doubt it.
Best Summary of Arch: http://www.archtherapeutics.blogspot.com/
The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery (some have estimated potentially up to 60%).
"The operation would be much shorter. We go from a bypass surgery that may take six hours to a bypass surgery that may take 45 minutes. Or a neurosurgery that may take three or four hours, to one that takes 20 minutes. So, it completely changes how you think about surgery.” “And it’s not just hemostasis. If you look at surgery for instance, let’s say we create a barrier that will stop the movement of bacteria. It will stop the growth of bacteria, and if you could stop the possible infection in that operating room, the recovery time would be faster.”
http://www.pnas.org/site/misc/ellis-behnkePodcastTranscript.pdf
So exactly why would a JNJ or Baxter want to do a JV with Arch after CE mark obtained in 2016? Wait for 2018?
Arch "Only" has to spend $ 6 to $10 million to get FULL US and Europe approvals. That is it. This is medical device so tests are relatively quick.
Of course not. Think about it. They are going to do a JV with JNJ or Baxter to SELL WHAT??? Of course it is the major external items they go after IMMEDIATELY upon approvals.
In Europe once the human trial is complete and CE Mark obtained and JV announced Pressure Ulcers or Bedsores and other external apps should be marketed by year end or early next
Right sales in Europe by end of year for the external uses which dwarf the internal uses.
First Welcome ! Second Congrats !
You are not the only one to have met the principals.
Read the 70 posts of G Smith---he and his family own a couple
million shares--he is for real based upon some statements about personalities and quirks that I know are true and few people would know without meeting them
http://seekingalpha.com/user/35157405/activity-feed#view=activity_feed
Read the Elevator Summary of ARCH
http://www.archtherapeutics.blogspot.com/
Watch
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
You Tube Video
AC5 ADDITIVES
Yes I have talked about the fact there are going to be all kinds of additives to AC5 to enhance healing, prevent infections, etc etc. That will be AC5 on steroids developed by Arch's JV partner or others. Next Generation AC5
This is an amazing informative Arch video
A Story in the FUTURE
Source: Doctor shareholder of ARCH
It is midnight in rural America. At the tiny emergency facility there are no doctors on staff at this time. A person is rushed to the facility puking blood. What does the nurse do? She has him drink AC5 to stop the bleeding. Next day the doctor addresses the cause of the bleeding.
So Arch is about to be at a very interesting crossroad. Do they joint venture all 200+- AC5 applications and lock them up with one party? Or do they narrow it to just certain external ones? Don't know the answer but it is a very interesting jigsaw puzzle.
When they sell out do they get any value for the applications that are not being used because of additional testing required?
We know the total additional capital required to rollout cost for Europe and USA is $ 6 to $ 10 million. In the biotech world that is TINY.
Dr. Norchi will not be in his element until Arch is uplisted and shown in all its true colors. He has had 10 years to prepare for this moment. If you listen to his presentations over last couple years they have become more and more polished.
He did 8 presentations in 2015. We are due for one soon.
Actually the external use applications will dwarf the internal use applications in terms of $$$. Of the 200 +- AC5 applications how many relate to external versus internal?
Pressure Ulcers alone in USA is 2.5 million cases costing over $ 10 Billion. Google that. Britian is another $ 2 billion
Closure Medical sold for $ 375 million in March 2005 to JNJ. Key Executives have helped Arch from Closure. Google that. Dermabond is in Liquid band aid.
Dr. Norchi is from the conservative camp on everything. Look at his ridiculous Pressure Ulcer numbers in the company presentation. He has 3 AC5 applications--What about the other 197+-?
What a great story !!!
Attributes of AC5
Synthetic peptide
Clear liquid, squirted or sprayed-- Can see and operate through it
Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body)
Classified as Medical Device in Europe because of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes
Stops bleeding promptly
Faster time to stop bleeding versus five different popular marketed products
Blood thinner agnostic—only hemostasis product that is.
Efficacy even in presence of “blood thinners”
Bioasborbable
Natural amino acids, non-animal
Enables normal healing
Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer
Stores at room temperature
Indefinite shelf life
Simple, effective, versatile, safe universal
Next Generation Medical Technology
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems.
That could be person with warrants exercising and because of 4.99% blocker provision had to sell equivalent shares. Where are you seeing that? Thanks
Sorry it is a registration of shares to remove restrictions from sale and it does not mean they will be hitting the market anytime soon. When they did the private placement Arch agreed to register the shares and warrants (shares issued upon exercise of the warrants).
The S-1 is boilerplate and it assumes a holder will sell. Those private placement investors are long term holders. I have followed all their holdings from day one. They are not in this for a nickel.
What is true is the private placement holders agree to what is called a "blocker provision" which means they agree not to go over 5%. So if they decide to exercise their Series E warrants (or any other warrants held) they would sell shares to stay below the 5%. However the Series E warrants run to 2021. They can waive the blocker provision and go over 5% and do the appropriate SEC filings.
Gobblygook nonsense.
BK not to ever rain on your fine parade. I know the numbers in the Company presentation are below conservative and do NOT take into account the 200 +/- POTENTIAL AC5 application. The company presentation addresses less than 5. What about the other 195?
For example, Pressure Ulcers or Bedsores afflicts 2.5 million in USA every year. It costs $10 billion. All kinds of lawsuits, etc. England alone is another $ 2 billion. Worlwide Presure Ulcers??
The easy low hanging fruit is the external applications for AC5---ones that can be rolled out after the human clinical trials and CE Mark approval and a JV partner.
Add Foot Ulcers. It goes on and on.
The floor is all yours BK.....
Good Friend. Invest and spread the word.
The CEO Dr. Norchi teaches investment diversification.but has all his eggs in one basket: ARTH.
He knows a thing or two about investments as he is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund.
When this gets uplisted to a major exchange his experience should pay off in spades. That is the league he is use to.
He has had ten full years to think about the crossroads we are about to enter. Yes since 2006 when it was private to 2013 when it went public.
Arch has 200 +/- applications to get after...A lot for this tiny company.
Perfect timing. A lot happening over next several months. 200+/- applications for AC5. Low market cap. A liquid medical device of all things.
How did you find us? It is well below the radar screen. Welcome...
Problem is that no one knows about Arch but a few people and until that changes it is going no where.
Well that's 123 of the 200 potential applications for AC5.
Let's see, bedsores in USA afflicts 2.5 million costing $ 10 Billion..
Thank you BK. My ignorance.
Arch Anesthesiologist--From Seeking Alpa
22nowind
Comments (247) |+ Follow |Send Message
Musings from 30 plus years in the O.R. as anesthesiologist. Lots of BLEEDING(emptied blood banks and yes exsanguination) from multiple sources. I don't think there is too much of an argument, for MAJOR BLEEDING like Abdominal /Thoracic/Splenic Artery aneurysm ruptures, Carotid/ Jugular trauma, heart trauma itself etc. major artery bleeding treated with suturing/patch/graph is the treatment of choice. But so often unless dire emergency getting to source of major bleed is fraught with many many minor bleeds, that not only take time to control with suture ligation and cautery, but clouds the visual field. This AC5 product would be ideal.
Also, in areas where there is no distinctive/obvious vessel to ligate like uterine/liver sinuses, but bleeding oozing is evident, again AC5 would be ideal(at site). Bleeding can be very clandestine, normal vital signs one minute, next bottom falls out!!!
Also, I think as mentioned, trapped blood/hematomas are a wonderful culture medium for bacteria. Bacteria are grown for analysis in path labs on Blood agar plates. The association with M.I.T. major league and know it quite well with brief but intense exposure. Thanks to one of S/A contributors Electric Phred was intro to Arch. For this price, potential market, reward far outweighs risk, people on team running it, and associations(M.I.T.) this is a NO BRAINER for this dude. Emptying the piggy bank buying as soon as markets open 5-31-16. Heck this is far far more secure than ANY lottery ticket or ANY casino. Thanks EP.
Summary of Capital Arch Therapeutics 2013-2016
Net Cash Used in Operations
2016 $ 3,130,851.00 8 Months EST.
2015 $ 4,239,386.00
2014 3,348,502.00
2013 1,434,620.00
Total Used in Operations $ 12,153,359.00
Capital Raised
2013
Common Stock Sold $ 2,000,000.00
2014
Common Stock Sold $ 2,624,703.00
Note Payable $ 1,000,000.00
2015
Exercise of Warrants $ 3,600,000.00
Common Stock Sold $ 3,015,966.00
Convertible Note $ 750,000.00
2016
Exercise of Warrants $ 1,040,000.00
Common Stock Sold $ 3,400,000.00
Total Capital Raised $ 17,430,669.00
Estimated Cash Today $ 5,277,310.00
Additional Cash required for full European and USA
Human Clinical Trials WAS $10 -14 Million NOW $6.1 - $10.1 Million
Burn Rate is approximately $ 400,000 month--good for a year.
The $6 to $10 million is peanuts !!!!!!!!!!!
"I think I should subscribe to stockgumshoe and take closer Look what they think."
Good idea. Make sure you read all the comments in the dropbox from:
"I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities."
http://www.stockgumshoe.com/author/dr-kss-md-phd/
3DM would never post the timing because it would be in minutes. I can tell you that I have talked with someone who has tried 3DM product and it does not work well.
We do have intellectual laws in the world and they rule not anything else. If you do not believe the inventor then you will believe no one. You can get a CE Mark without human trials. As I have already said they are all talk and no action. They have made many false statements. Go read all the patents that Arch has recently received.
Pay $ 49 and go here and read thousands of comments and analysis. Then go to their dropbox and read the hundred or so comments about the science including being the greatest medical discovery ever. Then come back here and share your findings.
Here
http://www.stockgumshoe.com/2015/08/microblog-discussion-re-arth/
I do not believe you understand the significance of this:
A CLEAR LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE....
Arch ties to JNJ
1) Dr. Arthur L. J. Rosenthal, Ph.D., also known as Art serves as Advisor of Arch Therapeutics, Inc. He served as a Vice President of Research and Development at Johnson & Johnson Medical, Inc., from April 1990 to January 1994, and was in charge of worldwide research, development, regulatory, and clinical affairs for the JJMI Division—Google Arthur L. J. Rosenthal Ph.D. to see his impressive background.
2) retired former COO of Arch William Cotter was one of key officers of Closure Medical Corporation which was sold to JNJ in 2005.See Arch press release Arch Therapeutics Appoints Senior Management Team Members CAMBRIDGE, MA -- (Marketwired) -- 07/08/13
Johnson & Johnson and CLOSURE Medical Corporation Announce Acquisition Agreement
Acquisition to Strengthen Presence in Topical Adhesives and Surgical Sealants
NEW BRUNSWICK, N.J. and RALEIGH, N.C., March 4, 2005
Thanks. I saw that but will any doctor use without human or even animal data?? Doctors rely on human data and who better to communicate than a major supplier.
BTW the market cap of 3D Matrix was $ 197 million versus Arcg's approximately $ 50 million. The only thing they have done right in past is raising capital.
Arch's flaw which has worked to our benefit is they formed as a reverse merger in 2013. They should have done a straight IPO and raised ALL the capital they needed for Europe and USA human trials--approximately $ 20 million. When they did the reverse merger they issued 3 for 1 warrants expecting exercise at higher prices. Well stock went down not up and they had to adjust the exercise price of the warrants. The exercise of these warrants have helped finance Arch.
Right now per public filings needs $ 10 to $ 14 million to complete Europe and USA human trials. This is tiny in the biotech world. BTW Arch has raised approximately $ 13 million since the reverse merger in 2013.
So we have a CEO who is a MD, MIT MBA adn and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund. He has stated he teaches diversification but has all his eggs in Arch. He has been building Arch since 2006. Public in 2013. He owns approximately 15 million shares and options of Arch. He is very very driven. He is also a great speaker. Watch some of his videos:
Company Video
Japanese 3D Matrix and Arch Therapeutics
Here is the bottom line summary:
Initial Intellectual property came out of MIT for both. The purpose of both companies was different. The regeneration part is 3-D Matrix LTD. and the hemostasis is Arch.
In the video presentation below Dr. Rutledge said that when they first tested the peptide out they thought they had something great ! iT WASN'T !
Not satisfied with that Dr. Rutledge sought out the best minds in the peptide field, put some of them on the Arch board and now they have the best peptide formulas in the world. They patented the crap out of it with one of the best intellectual property law firms in Boston.
http://www.pabstpatent.com/
My research indicates that 3DM ran with the original formulations and thats why they are nothing close to the formulation of AC5.
Based upon intellectual property:
3DM = Building and Regeneration of organs
Arch= Stopping and Blocking
The Inventor
The common thread between 3DM and Arch is the inventor Dr. Rutledge
Arch patent strategy and MIT
Both Arch and 3DM have MIT exclusive patents pertaining to different areas. 3DM primarily relates to regeneration technology whereas Arch pertains to hemostasis. In both cases licensing fees must be paid to MIT as a few % of sales. Dr. Rutledge Ellis-Behnke laid out the general basis of Arch and 3DM in the interview in 2009 here:
http://www.pnas.org/site/misc/ellis-behnkePodcastTranscript.pdf
Presentation by Founder of AC5 Dr. Rutledge Ellis-Behnke PHD using AC5 on animals
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
You Tube Video --notice Dr. Rutledge discloses ownership in Arch but nothing for 3DM--notice mention of how primitive the first AC5 was (2006-07)